Methods of assessment of n-3 long-chain polyunsaturated fatty acid status in humans

A systematic review

Katalin Fekete, Tamás Marosvölgyi, Viktória Jakobik, T. Decsi

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Background: The availability of reliable biomarkers of n-3 (omega-3) long-chain polyunsaturated fatty acid (LCPUFA) status is a prerequisite for linking dietary n-3 LCPUFA status to clinical outcomes. Objective: The objective of this meta-analysis was to assess the usefulness of different biomarkers of n-3 LCPUFA status in healthy humans. Design: We searched Ovid MEDLINE, EMBASE (Ovid), and Cochrane databases from inception to September 2007 for human intervention studies in which n-3 LCPUFA status changed after ≥2 wk of n-3 LCPUFA supplementation. We used formal inclusion/exclusion criteria and applied standard procedures for data extraction, validity assessment, and meta-analysis. Results: We included 41 studies (34 randomized controlled trials and 7 before-after studies) reporting on 18 different biomarkers. The data allowed specific evaluation of biomarkers of docosahex-aenoic acid (DHA, 22:6n-3) and eicosapentaenoic acid (EPA, 20:5n-3) status in response to supplementation. There were sufficient data to determine that plasma DHA, plasma phospholipid DHA, plasma triacylglycerol DHA, plasma cholesteryl ester DHA, plasma nonesterified DHA, erythrocyte DHA, erythrocyte phospholipid DHA, and platelet DHA were all effective biomarkers of DHA status and that plasma phospholipid EPA was an effective marker of EPA status. Plasma phospholipid DHA appears to be a good marker of DHA status in adult men and women irrespective of DHA baseline status or supplementation dose, but its usefulness in other population subgroups is unclear. Conclusion: There appears to be a range of useful biomarkers of DHA status in humans, but further research is needed to characterize which work best in particular population subgroups.

Original languageEnglish
JournalAmerican Journal of Clinical Nutrition
Volume89
Issue number6
DOIs
Publication statusPublished - Jan 6 2009

Fingerprint

Unsaturated Fatty Acids
Biomarkers
Phospholipids
Meta-Analysis
Erythrocytes
Eicosapentaenoic Acid
Cholesterol Esters
MEDLINE
Population
Triglycerides
Blood Platelets
Randomized Controlled Trials
Databases
Acids
Research

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Medicine(all)

Cite this

Methods of assessment of n-3 long-chain polyunsaturated fatty acid status in humans : A systematic review. / Fekete, Katalin; Marosvölgyi, Tamás; Jakobik, Viktória; Decsi, T.

In: American Journal of Clinical Nutrition, Vol. 89, No. 6, 06.01.2009.

Research output: Contribution to journalArticle

@article{45fced49960b44609a089f153936a611,
title = "Methods of assessment of n-3 long-chain polyunsaturated fatty acid status in humans: A systematic review",
abstract = "Background: The availability of reliable biomarkers of n-3 (omega-3) long-chain polyunsaturated fatty acid (LCPUFA) status is a prerequisite for linking dietary n-3 LCPUFA status to clinical outcomes. Objective: The objective of this meta-analysis was to assess the usefulness of different biomarkers of n-3 LCPUFA status in healthy humans. Design: We searched Ovid MEDLINE, EMBASE (Ovid), and Cochrane databases from inception to September 2007 for human intervention studies in which n-3 LCPUFA status changed after ≥2 wk of n-3 LCPUFA supplementation. We used formal inclusion/exclusion criteria and applied standard procedures for data extraction, validity assessment, and meta-analysis. Results: We included 41 studies (34 randomized controlled trials and 7 before-after studies) reporting on 18 different biomarkers. The data allowed specific evaluation of biomarkers of docosahex-aenoic acid (DHA, 22:6n-3) and eicosapentaenoic acid (EPA, 20:5n-3) status in response to supplementation. There were sufficient data to determine that plasma DHA, plasma phospholipid DHA, plasma triacylglycerol DHA, plasma cholesteryl ester DHA, plasma nonesterified DHA, erythrocyte DHA, erythrocyte phospholipid DHA, and platelet DHA were all effective biomarkers of DHA status and that plasma phospholipid EPA was an effective marker of EPA status. Plasma phospholipid DHA appears to be a good marker of DHA status in adult men and women irrespective of DHA baseline status or supplementation dose, but its usefulness in other population subgroups is unclear. Conclusion: There appears to be a range of useful biomarkers of DHA status in humans, but further research is needed to characterize which work best in particular population subgroups.",
author = "Katalin Fekete and Tam{\'a}s Marosv{\"o}lgyi and Vikt{\'o}ria Jakobik and T. Decsi",
year = "2009",
month = "1",
day = "6",
doi = "10.3945/ajcn.2009.27230I",
language = "English",
volume = "89",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "6",

}

TY - JOUR

T1 - Methods of assessment of n-3 long-chain polyunsaturated fatty acid status in humans

T2 - A systematic review

AU - Fekete, Katalin

AU - Marosvölgyi, Tamás

AU - Jakobik, Viktória

AU - Decsi, T.

PY - 2009/1/6

Y1 - 2009/1/6

N2 - Background: The availability of reliable biomarkers of n-3 (omega-3) long-chain polyunsaturated fatty acid (LCPUFA) status is a prerequisite for linking dietary n-3 LCPUFA status to clinical outcomes. Objective: The objective of this meta-analysis was to assess the usefulness of different biomarkers of n-3 LCPUFA status in healthy humans. Design: We searched Ovid MEDLINE, EMBASE (Ovid), and Cochrane databases from inception to September 2007 for human intervention studies in which n-3 LCPUFA status changed after ≥2 wk of n-3 LCPUFA supplementation. We used formal inclusion/exclusion criteria and applied standard procedures for data extraction, validity assessment, and meta-analysis. Results: We included 41 studies (34 randomized controlled trials and 7 before-after studies) reporting on 18 different biomarkers. The data allowed specific evaluation of biomarkers of docosahex-aenoic acid (DHA, 22:6n-3) and eicosapentaenoic acid (EPA, 20:5n-3) status in response to supplementation. There were sufficient data to determine that plasma DHA, plasma phospholipid DHA, plasma triacylglycerol DHA, plasma cholesteryl ester DHA, plasma nonesterified DHA, erythrocyte DHA, erythrocyte phospholipid DHA, and platelet DHA were all effective biomarkers of DHA status and that plasma phospholipid EPA was an effective marker of EPA status. Plasma phospholipid DHA appears to be a good marker of DHA status in adult men and women irrespective of DHA baseline status or supplementation dose, but its usefulness in other population subgroups is unclear. Conclusion: There appears to be a range of useful biomarkers of DHA status in humans, but further research is needed to characterize which work best in particular population subgroups.

AB - Background: The availability of reliable biomarkers of n-3 (omega-3) long-chain polyunsaturated fatty acid (LCPUFA) status is a prerequisite for linking dietary n-3 LCPUFA status to clinical outcomes. Objective: The objective of this meta-analysis was to assess the usefulness of different biomarkers of n-3 LCPUFA status in healthy humans. Design: We searched Ovid MEDLINE, EMBASE (Ovid), and Cochrane databases from inception to September 2007 for human intervention studies in which n-3 LCPUFA status changed after ≥2 wk of n-3 LCPUFA supplementation. We used formal inclusion/exclusion criteria and applied standard procedures for data extraction, validity assessment, and meta-analysis. Results: We included 41 studies (34 randomized controlled trials and 7 before-after studies) reporting on 18 different biomarkers. The data allowed specific evaluation of biomarkers of docosahex-aenoic acid (DHA, 22:6n-3) and eicosapentaenoic acid (EPA, 20:5n-3) status in response to supplementation. There were sufficient data to determine that plasma DHA, plasma phospholipid DHA, plasma triacylglycerol DHA, plasma cholesteryl ester DHA, plasma nonesterified DHA, erythrocyte DHA, erythrocyte phospholipid DHA, and platelet DHA were all effective biomarkers of DHA status and that plasma phospholipid EPA was an effective marker of EPA status. Plasma phospholipid DHA appears to be a good marker of DHA status in adult men and women irrespective of DHA baseline status or supplementation dose, but its usefulness in other population subgroups is unclear. Conclusion: There appears to be a range of useful biomarkers of DHA status in humans, but further research is needed to characterize which work best in particular population subgroups.

UR - http://www.scopus.com/inward/record.url?scp=66849141264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66849141264&partnerID=8YFLogxK

U2 - 10.3945/ajcn.2009.27230I

DO - 10.3945/ajcn.2009.27230I

M3 - Article

VL - 89

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 6

ER -